<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04658823</url>
  </required_header>
  <id_info>
    <org_study_id>T3-CAD-01</org_study_id>
    <nct_id>NCT04658823</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tocotrienols in CADASIL</brief_title>
  <official_title>A Randomized Placebo-controlled Double-blind Pilot / Phase II Study to Assess the Efficacy and Safety of HOV-12020 in Patients With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hovid Berhad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hovid Berhad</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CADASIL is a paradigmatic cerebral small vessel disease responsible for white-matter lesions,&#xD;
      accumulation of lacunes, microbleeds and cerebral atrophy. The disease is responsible for&#xD;
      stroke and cognitive decline associated with motor disability. The number of incident&#xD;
      lacunes, and amount of cerebral atrophy were recently found to have a strong relationship to&#xD;
      cognitive decline and disability progression over 3 years in a large sample of patients. Palm&#xD;
      tocotrienols has previously shown evidence of therapeutic effect in attenuating the&#xD;
      progression of WMH related to sporadic cerebral small vessel disease in a randomized&#xD;
      controlled clinical trial. We hypothesize that palm tocotrienols complex (HOV-12020) can&#xD;
      reduce the clinical progression in CADASIL.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of manifestations related to clinical worsening</measure>
    <time_frame>24 months</time_frame>
    <description>Occurrence one failure event within 24 months after Baseline. A failure event is considered when at least one of the following manifestations is detected during the study period:&#xD;
incident stroke&#xD;
increase of disability corresponding to an increase in the mRS score of at least 1 point to result in a score of 2 or greater&#xD;
cognitive decline corresponding to a reduction of at least 4 points of the VADAS-Cog score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>24 months</time_frame>
    <description>Number of serious AEs, type of severe AEs, Total number of AEs</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change of cognitive performance on CDR</measure>
    <time_frame>24 months</time_frame>
    <description>Individual variation of different cognitive measures obtained using the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB); score 0 to 18</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of cognitive performances on MDRS</measure>
    <time_frame>24 months</time_frame>
    <description>Individual variation of different cognitive measures obtained using the Mattis Dementia Rating Scale (MDRS); score 0 to 144</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of cognitive performances on sub-subscale of MDRS</measure>
    <time_frame>24 months</time_frame>
    <description>Individual variation of different cognitive measures obtained using the initiation/perseveration subscale of the MDRS (MDRS-I/P); score 0 to 37</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of cognitive performances on TMT</measure>
    <time_frame>24 months</time_frame>
    <description>Individual variation of different cognitive measures obtained using the Trail Making Test Part A and B time</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes of gait and balance performances on SPPB</measure>
    <time_frame>24 months</time_frame>
    <description>Between group difference on individual changes of the Short Physical Performance Battery (SPPB) score; score 0 (worst) to 12 (best)</description>
  </other_outcome>
  <other_outcome>
    <measure>Effects on Quality of life using SF3-6</measure>
    <time_frame>24 months</time_frame>
    <description>Between group differences in patient reported outcomes as assessed by the Short Form-36 (SF-36), score 0 to 100</description>
  </other_outcome>
  <other_outcome>
    <measure>Effects on Quality of life, using DAD</measure>
    <time_frame>24 months</time_frame>
    <description>Between group differences in patient reported outcomes as assessed by the Disability Assessment for Dementia (DAD) scores; score 0 to 100</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cadasil</condition>
  <arm_group>
    <arm_group_label>HOV-12020</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palm tocotrienols complex Oral softgel capsule (containing 285mg mixed tocotrienols and tocopherol)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Oral Softgel capsule (each capsule containing vitamin E stripped soybean oil)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HOV-12020 (Palm tocotrienols complex)</intervention_name>
    <description>Oral Softgel capsule containing mixed tocotrienols and tocopherol with enhanced absorption delivery system; 1 capsule twice daily</description>
    <arm_group_label>HOV-12020</arm_group_label>
    <other_name>HOV-12020</other_name>
    <other_name>Palm Vitamin E</other_name>
    <other_name>Tocotrienols</other_name>
    <other_name>Tocovid Suprabio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral Softgel capsule containing soybean oil; 1 capsule twice daily</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female&#xD;
&#xD;
          2. Participants aged 45 to 75 years inclusive, at the time of signing of informed consent&#xD;
&#xD;
          3. Confirmed Diagnosis of CADASIL, defined by either:&#xD;
&#xD;
               -  A Typical mutation in the NOTCH3 gene responsible for an odd number of cystein&#xD;
                  residue OR&#xD;
&#xD;
               -  A positive skin biopsy showing typical granular osmiophilic material (GOM) in the&#xD;
                  vascular wall of small vessels with electron microscopy&#xD;
&#xD;
          4. Presence of at least one prevalent lacune on the MRI identified on 3DT1 or FLAIR&#xD;
             images.&#xD;
&#xD;
          5. Presence of Confluent white matter hyperintensities (WMH) on T2-weighted or FLAIR MR&#xD;
             images (Fazekas grade 2-3).&#xD;
&#xD;
          6. MMSE score ≥15&#xD;
&#xD;
          7. mRS at 0 - 3&#xD;
&#xD;
          8. A woman of child bearing potential (WOCBP) is eligible to participate if she is not&#xD;
             pregnant, not breastfeeding, and agrees to follow contraceptive guidance (as described&#xD;
             in Appendix 5) provided by the study clinician during the treatment period and for 28&#xD;
             days after the last dose of the study treatment.&#xD;
&#xD;
          9. Capable of giving signed informed consent and have a patient representative willing to&#xD;
             co-sign informed consent, which includes compliance with the requirements and&#xD;
             restrictions listed in the informed consent form (ICF) and in this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinical stroke with persisting neurological deficit within 6 months prior to&#xD;
             Screening.&#xD;
&#xD;
          2. Any other neurodegenerative disorder, such as Parkinson's disease, Alzheimer's&#xD;
             disease, or Huntington's disease.&#xD;
&#xD;
          3. Current significant hematological, cardiac, pulmonary, metabolic, neurologic or&#xD;
             psychiatric disorders, uncontrolled seizures, untreated hypertension, disorders&#xD;
             increasing risk of bleeding (Hemophilia), or any other significant active medical&#xD;
             condition which in the Investigator's opinion would impact participation in this&#xD;
             study.&#xD;
&#xD;
          4. History of myocardial infarction within 3 months prior to Screening, or current active&#xD;
             angina pectoris, or symptomatic heart failure.&#xD;
&#xD;
          5. History of cancer, within the past 5 years. Patients with basal cell carcinoma,&#xD;
             squamous cell carcinoma, and Stage 1 prostate cancer can be included in the study.&#xD;
&#xD;
          6. An episode of major depression within the last 6 months prior to Screening (clinically&#xD;
             stable minor depression is not exclusionary).&#xD;
&#xD;
          7. History of attempted suicide within 6 months prior to Screening or a positive response&#xD;
             to items 4 or 5 of Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening and&#xD;
             Baseline.&#xD;
&#xD;
          8. History of drug or alcohol abuse or dependence.&#xD;
&#xD;
          9. Contra-indications to MRI: presence of a pacemaker, severe claustrophobia, cochlear&#xD;
             implants, ferromagnetic devices or clips, intracranial vascular clips, insulin pumps,&#xD;
             metallic implants.&#xD;
&#xD;
         10. Pregnancy or breastfeeding women.&#xD;
&#xD;
         11. History of human immunodeficiency virus (HIV), hepatitis B or C.&#xD;
&#xD;
         12. History of allergy or severe intolerance to Vitamin E (tocopherols / tocotrienols).&#xD;
&#xD;
         13. Presence at Screening of alanine aminotransferase (ALT), aspartate aminotransferase&#xD;
             (AST), amylase, or lipase 2x above the upper limit of normal (ULN) of laboratory&#xD;
             reference range, total bilirubin 1.5x ULN, any other clinically significant laboratory&#xD;
             abnormality.&#xD;
&#xD;
         14. Presence at Screening of Creatinine clearance &lt;60 (estimated by Cockcroft-Gault&#xD;
             equation).&#xD;
&#xD;
         15. Cognitive enhancers such as donepezil, are allowed only if stable dosage within 3&#xD;
             months prior to Screening.&#xD;
&#xD;
         16. Use of tocotrienol supplementation within 3 months prior to Screening or any current&#xD;
             use of Vitamin E other than study drug (all other vitamin supplements are allowed, if&#xD;
             stable dosage within 3 months prior to screening).&#xD;
&#xD;
         17. Participation in a clinical trial with investigational product (IP) within 30 days&#xD;
             prior to Screening. Patients participating in observational studies with no IP, will&#xD;
             be allowed to participate in this study&#xD;
&#xD;
         18. Indication for anti-coagulant therapy&#xD;
&#xD;
         19. Patients with known sensitivity to polyoxyl castor oil or risk of allergy to soybean&#xD;
             and peanuts.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pr Hugues Chabriat</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Lariboisière APHP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Ho</last_name>
    <role>Study Director</role>
    <affiliation>Hovid Berhad</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pr Hugues Chabriat</last_name>
    <phone>33 (0)1 49952597</phone>
    <email>hugues.chabriat@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Estelle Dubus, PhD</last_name>
    <phone>33 (0)1 4995 8391</phone>
    <email>estelle.dubus@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Lariboisière APHP</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estelle Dubus, PhD</last_name>
      <phone>33 (0)1 4995 8391</phone>
      <email>estelle.dubus@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Pr Hugues Chabriat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 29, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>December 21, 2020</last_update_submitted>
  <last_update_submitted_qc>December 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CADASIL</keyword>
  <keyword>Tocotrienols</keyword>
  <keyword>Vitamin E</keyword>
  <keyword>Vascular</keyword>
  <keyword>Stroke</keyword>
  <keyword>Dementia</keyword>
  <keyword>Cerebral Small Vessel Disease</keyword>
  <keyword>Cognitive disorder</keyword>
  <keyword>Neurovascular disease</keyword>
  <keyword>Hereditary multi-infarct</keyword>
  <keyword>Cerebrovascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>CADASIL</mesh_term>
    <mesh_term>Dementia, Multi-Infarct</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>Tocovid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

